Satellos Bioscience Inc. MSLE
Satellos Bioscience Inc. (Nasdaq: MSLE) is a rare genetic drug developer. Its lead program, Forazapadin (SAT-3247), oral AAK1 inhibitor, is in Phase 2 for Duchenne muscular dystrophy (DMD). Its next catalyst on record is forazapadin: Satellos expects to begin a Phase 2 clinical trial of forazapadin in adults with FSHD in the fourth quarter of 2026 following FDA clearance of an IND. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: forazapadin — Satellos expects to begin a Phase 2 clinical trial of forazapadin in adults with FSHD in the fourth quarter of 2026 following FDA clearance of an IND. (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Forazapadin (SAT-3247) - BASECAMP (pediatric DMD, randomized placebo-controlled) | DMD | small molecule | Phase 2 |
| Forazapadin (SAT-3247) - TRAILHEAD (adult DMD, open-label long-term follow-up) | DMD | small molecule | Phase 2 |
| Forazapadin (SAT-3247) - FSHD adults | Facioscapulohumeral muscular dystrophy (FSHD) | small molecule | Pre-clinical |
| SAT-3153 (back-up AAK1 inhibitor) | DMD | small molecule | Pre-clinical |
Recent results and decisions
- Nov 6, 2026submitted Satellos submitted protocol amendment to change primary efficacy endpoint in BASECAMP Phase 2 trial to MRI-measured fat fraction following FDA feedback.
Protocol amendment submitted to implement the new primary efficacy endpoint
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.